ArticleTranslational cancer research2025
Investigating additional malignancy rates and prognostic factors in multiple myeloma patients: a Surveillance, Epidemiology, and End Results (SEER) database retrospective cohort study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.Blood cancer journal · 2026Article
- Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective treatments have improved survival in multiple myeloma (MM), but the extension of survival has increased the risk of additional malignancies. Existing staging systems, such as the Durie-Salmon (D-S) staging system and the Revised International Staging System (R-ISS), lack comprehensive data on malignancy-related complications. With the aim of improving outcomes, in this study, we investigated additional malignancy rates, latency periods, and prognostic factors in MM patients using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: Data from MM patients with additional malignancies [1992-2020] were extracted from SEER. Patients meeting International Classification of Diseases for Oncology, Third Edition (ICD-O-3) criteria were included, excluding those with MM as the sole primary malignancy (PM). Variables analyzed included age, sex, race, latency period, tumor number, sequence, and malignancies sites. Standardized incidence ratio (SIR) and Cox regressions were used to assess risks and survival factors. Two nomograms were developed for prognosis prediction. Results: Among 60,550 MM patients, 3,676 (6.07%) developed second primary malignancies (SPMs), and 1,663 (2.75%) had primary malignancies (PMs). Prostate cancer was the most solid tumor, whereas non-Hodgkin's lymphoma (NHL) was the leading hematologic malignancy. Among MM patients with SPMs, the median follow-up duration was 60 months, and the overall survival (OS) rate was 28.63%. The following key risk factors were identified: older age at MM diagnosis [≥80 Conclusions: This study highlights key risk factors for additional malignancies in MM patients, including advanced age, NHL, and higher sequence numbers. The developed nomograms aid in predicting survival outcomes, enabling personalized clinical decisions and improved patient management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.